Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best biotech stocks to buy. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) participated in the Bank of America Global Healthcare Conference 2025 on September 23. During the conference, the company presented a strategic review of its robust pipeline, encompassing both encouraging advancements and possible barriers.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported that it has five phase 3 initiatives in progress and is focusing on commercial launches for LifTrak, Casgevy, and Jurnavix. Patients with cystic fibrosis have begun utilizing LifTrak at a rapid rate, especially those with uncommon mutations. Meanwhile, Jurnavix has addressed the need for non-opioid pain management by gaining widespread coverage in the United States.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) also expects to surpass its upper-end operating expense forecast of $5 billion in 2025. The company attributes this to investments in external innovation, improved marketing for Jurnavix, and quicker enrollment in clinical trials.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that is involved in the discovery and development of small-molecule medications for the treatment of severe illnesses, including cystic fibrosis.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.